🇺🇸 FDA
Patent

US 8445507

Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

granted A61KA61K31/4439A61K9/48

Quick answer

US patent 8445507 (Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases) held by The Regents of the University of California expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/4439, A61K9/48, A61P, A61P13/08